| 2024-11-13 | +0.94 % |
|
| 2024-11-11 | -2.91 % |
|
| 2024-11-08 | +2.84 % |
|
| 2024-11-04 | +0.36 % |
|
| 2024-11-01 | -1.02 % |
|
| 2024-10-31 | +0.19 % |
|
| 2024-10-30 | +1 % |
|
| 2024-10-29 | -1.26 % |
|
| 2024-10-28 | -0.28 % |
|
| 2024-10-24 | +0.4 % |
|
| 2024-10-23 | -1.02 % |
|
| 2024-10-22 | -0.67 % |
|
| 2024-10-21 | -1.02 % |
|
| 2024-10-18 | -3.15 % |
|
| 2024-10-17 | +2.36 % |
|
| 2024-10-16 | +0.61 % |
|
| 2024-10-15 | -0.11 % |
|
| 2024-10-14 | +0.65 % |
|
| 2024-10-10 | +1.75 % |
|
| 2024-10-09 | +1.97 % |
|
| 2024-10-08 | +2.3 % |
|
| 2024-10-04 | +0.39 % |
|
| 2024-10-01 | +1.01 % |
|
| 2024-09-27 | -0.06 % |
|
| 2024-09-26 | +0.3 % |
|
| 2024-09-11 | +0.84 % |
|
| 2024-09-04 | +0.6 % |
|
| 2024-08-30 | +0.51 % |
|
| 2024-08-13 | +0.66 % |
|
| 2024-08-12 | -0.84 % |
|
| 2024-08-07 | -1.77 % |
|
| 2024-08-06 | -0.55 % |
|
| 2024-08-05 | -3.55 % |
|
| 2024-08-02 | -2.24 % |
|
| 2024-08-01 | +2.03 % |
|
| 2024-07-25 | +0.3 % |
|
| 2024-07-24 | +0.1 % |
|
| 2024-07-22 | +0.88 % |
|
| 2024-07-12 | -0.69 % |
- Vertex Pharmaceuticals (VRTX) stock went down by -0.69% last night following an insider transaction where Dr. Carmen Bozic, the EVP and CMO, sold 2,280 shares of the company's common stock, valued at $1,111,135, due to a prearranged trading plan, although the stock reduction may not necessarily reflect the company's outlook.
- The Vertex Pharmaceuticals (VRTX) stock went down because the Executive Vice President and Chief Medical Officer sold 2,280 shares at $487.34 per share, leading to concerns that the stock may be overvalued as the price-to-GF-Value ratio is high.
|
| 2024-07-05 | +0.91 % |
|
| 2024-06-28 | -0.8 % |
|
| 2024-06-24 | +1.33 % |
|
| 2024-06-20 | +0.88 % |
|
| 2024-06-14 | +0.35 % |
|
| 2024-06-13 | +0.68 % |
|
| 2024-06-11 | -0.36 % |
|
| 2024-06-10 | +0.05 % |
|
| 2024-06-07 | -0.51 % |
|
| 2024-06-05 | +1.7 % |
|
| 2024-06-04 | +1.01 % |
- Vertex Pharmaceuticals (VRTX) stock went up by 1.01% last night after an insider, Ourania Tatsis, executed a sale of 4,600 shares at $441.99 per share, making investors interested in tracking insider behaviors and evaluating the stock's valuation metrics in relation to its current trading price.
- Vertex Pharmaceuticals (VRTX) stock was up 1.01% last night due to positive outlook provided by the CEO and President, Reshma Kewalramani, during the William Blair 44th Annual Growth Stock Conference, highlighting expectations for future financial performance, multiple potential product launches, advancement in research and development, and expanding into new disease areas such as acute pain, sickle cell disease, and beta thalassemia.
|
| 2024-06-03 | +3.26 % |
|
| 2024-05-31 | +2.77 % |
|
| 2024-05-29 | -1.29 % |
|
| 2024-05-28 | -2.2 % |
|
| 2024-05-23 | +0.73 % |
|
